Novanta stock tumbles 6.6% to start 2026; traders eye Jan. 14 management talks
4 January 2026
1 min read

Novanta stock tumbles 6.6% to start 2026; traders eye Jan. 14 management talks

NEW YORK, January 3, 2026, 20:47 ET — Market closed

  • Novanta shares fell 6.6% on Friday, the first U.S. session of 2026, closing at $111.14. 1
  • The drop came in a holiday-thinned market as U.S. stocks ended mixed and Treasury yields climbed. 2
  • Investors are watching Jan. 14 conference presentations and next week’s U.S. jobs and inflation data for direction. 3

Novanta Inc. shares fell 6.6% on Friday, closing at $111.14 after touching an intraday low of $110.25, according to data from Twelve Data. 1

The move stood out because it landed on the first trading day of 2026, when many investors were still returning from year-end breaks and liquidity can be thinner. U.S. stocks finished mixed in that session as Treasury yields rose. 2

“Today is kind of a holiday trading day, lighter volumes, people not engaged normally,” said Jed Ellerbroek, portfolio manager at Argent Capital in St. Louis. 2

Novanta opened at $119.89 and never regained its footing, ending the day near the bottom of its $110.25 to $119.89 range. Volume was about 662,700 shares. 1

The slide pushed the stock below the $120 area it had recently traded around, after a string of late-December closes near $119 to $123. 1

Novanta sells core technology solutions to medical, life science and advanced industrial equipment makers, the company says, exposing it to shifts in end-market demand and capital spending cycles. 4

With no fresh company announcements flagged in the past two weeks on its investor relations news feed, investors have shifted focus to near-term events where executives could reset expectations for 2026. 5

Management is scheduled to present on January 14 at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco, with CEO Matthijs Glastra and CFO Robert Buckley slated to speak, the company said in a press release. 3

That same day, COO Chuck Ravetto is set to participate in CJS Securities’ investor conference, also disclosed by the company. 6

On earnings timing, Nasdaq and Zacks currently peg Novanta’s next quarterly report around February 24, though those calendars note the date is not confirmed by the company. 7

Before next session

Macro data could matter as much as company-specific updates. Reuters said investors are watching the monthly U.S. employment report due January 9 and the consumer price index due January 13 for clues on the pace of rate cuts in 2026. 8

Rate expectations feed directly into valuations for smaller growth and industrial-technology names, and Reuters noted the market “is looking for direction” after finishing 2025 near the same level as late October. 8

On the charts, traders often watch Friday’s low near $110 as immediate support and the $120 zone as a first resistance level after the stock’s break lower; a return above that area would suggest selling pressure is easing. 1

Stock Market Today

NAB share price in focus after Friday slide as rate rises and bank updates loom

NAB share price in focus after Friday slide as rate rises and bank updates loom

8 February 2026
National Australia Bank shares closed down 1.6% at A$43.36 on Friday after the S&P/ASX 200 fell nearly 2%, its worst session in almost a year. NAB, CBA, and Westpac will raise variable mortgage rates by 0.25% following the Reserve Bank’s hike to 3.85%. Key sector results are due from CBA on Feb. 11, Westpac on Feb. 13, and NAB on Feb. 18.
CSL Limited stock in focus: what to watch before Monday as half-year results loom

CSL Limited stock in focus: what to watch before Monday as half-year results loom

8 February 2026
CSL Ltd shares closed at A$180.50 on Friday, down 0.4%, ahead of its half-year results due Feb. 11. Around 1.23 million shares changed hands as the S&P/ASX 200 slid 2%. The company last cut its outlook in October, citing weaker U.S. flu vaccine demand. Investors await Wednesday’s update and interim dividend decision.
Guidewire stock sinks 6.7%: GWRE slides below $190 as traders eye next earnings
Previous Story

Guidewire stock sinks 6.7%: GWRE slides below $190 as traders eye next earnings

Kymera Therapeutics (KYMR) stock drops 6.6% to start 2026 as insider sale filing stays in focus
Next Story

Kymera Therapeutics (KYMR) stock drops 6.6% to start 2026 as insider sale filing stays in focus

Go toTop